Stockreport

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a p [Read more]